# ClinicalTrials.gov record NCT06987695

> PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06987695-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06987695-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06987695-maridebart-cafraglutide-v1.json
- Content SHA-256: `dcdab8aee486a5c7f4be897e55fae7bdcac758b31279c783ccb51746be9502c5`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06987695 ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

## Sources

<a id="source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965"></a>
- **ClinicalTrials.gov record NCT06987695 · retained source version 2025-12-17:6b02adf2b9653a7e1104f8657f56e6753e437be3897ab65b54cbc4c013f2bc18** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06987695) (`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06987695." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06987695-maridebart-cafraglutide-v1.json SHA-256: dcdab8aee486a5c7f4be897e55fae7bdcac758b31279c783ccb51746be9502c5.